Pathogenetic substantiation of advantages and duration of phytoselective therapy of the menstrual cycle disorders




menstrual disorders, duration of therapy, monotherapy, Tazalok


One of the urgent modern problems is determining the optimal medicine for treatment of menstrual irregularities and duration of therapy.

Objective of the study was to determine the optimal treatment period of menstrual irregularities with TazalokTM, as well as the comparative effectiveness of the therapy results with a derivative drug of Vitex agnus-castus.

Design: a comparative study.

Materials and methods. Analysis of retrospective data and dynamic observation of 120 patients 23–37 years old with menstrual irregularities who received monotherapy with TazalokTM and Vitex agnus castus was carried out. 60 patients received drugs for 3 months (group I TazalokTM and group II Vitex agnus-castus), and 60 patients for 6 months

(group III TazalokTM and group IV Vitex agnus-castus). Groups are divided into subgroups depending on the menstruation nature: A – heavy, B – meager menstruation. All patients underwent a hormonal examination after 6 months (the results of the previous three-month therapy were considered initial), sonographic study, and dynamics of the pain syndrome were assessed according to the visual analogue scale.

Study results. Subgroups IIIA and IIIB (TazalokTM for 6 months) showed the best clinical results and data from hormonal tests, sonography of the pelvic organs, mammary glands, thyroid gland; elimination of pain. An increase in progesterone levels, normalization of estradiol levels, follicle-stimulating hormone, and luteinizing hormone has been observed. Normalization of thyroid function was found in patients taking TazalokTM. Groups IVA and IVB (Vitex agnus-castus for 6 months) showed mainly a decrease in prolactin levels, normalization of mammary echography. The advantage of TazalokTM using also consisted in cortisol normalizing, one of the main pathogenetic factors for menstrual irregularities. Conclusion. TazalokTM is the drug of choice for monotherapy of menstrual irregularities, demonstrates the advantages of hormonal and clinical correction of pathological conditions in relation to Vitex agnus-castus; the 6 months treatment period should be considered optimal.

Author Biographies

О. В. Грищенко, Kharkiv Medical Academy of Postgraduate Education, Kharkiv

MD, professor, head of the Perinatology, Obstetrics and Gynecology Department

В. В. Бобрицкая, Kharkiv Medical Academy of Postgraduate Education, Kharkiv

PhD, associate professor at the Perinatology, Obstetrics and Gynecology Department


  1. Vorontsova, Z.A., Minasyan, V.V. “Some results of experimental studies of the organs of the neuroendocrine system (brief literature review).” J New Medical Technologies, eEdition 6 (2018): 336–9.
  2. “Luteal phase deficiency correction in women of reproductive age at hypothyroidism background.” Reproductive endocrinology 5.19 (2014): 98–101.
  3. Grishchenko, O.V., Bobrytska, V.V. “New patterns of menstrual disorders’ treatment – unification of the method.” Reproductive endocrinology 3/47 (2019): 26–32.
  4. International Statistical Classification of Diseases and Related Health Problems of the Tenth Review (ICD-10).
  5. Seidlova-Wuttke, D., Wuttke, W. “The premenstrual syndrome, premenstrual mastodynia, fibrocystic mastopathy and infertility have often common roots. Effects of extracts of chasteberry (Vitex agnus-castus) as a solution.” Reproductive endocrinology 1.45 (2019): 66–74.
  6. Kurkin, V.A., Kurkina, A.V., Zaitсeva, E.N., et al. “Investigation of diuretic activity of phytopreparations of calendula officinalis L. flowers.” Bulletin of Siberian Medicine 15.2 (2016): 51–7.
  7. Tatarchuk, T.F., Ganzhyi, I.Y., Pedachenko, N.Y., Kapshuk, I.N. “Modern nonhormonal possibilities of treatment of polycystic ovary syndrome in obese women.” Reproductive endocrinology 5.13 (2013): 14–21.
  8. Smolanka, I.I. “Treatment of fibrocystic breast disease – a way to prevent breast cancer.” Reproductive endocrinology 2.22 (2015): 65–9.
  9. Yashina, E.G., Lasachko, S.A. “Clinico-pathogenetic substantiation of correction failure luteal phase of the menstrual cycle in women with breast dyshormonal diseases.” Women’s Health 4.90 (2014): 115–9.
  10. Berga, S., Genazzani, A.R., Naftolin, F., Petraglia, F. “Menstrual Cycle Related Disorders.” Frontiers in Gynecological Endocrinology 7.1 (2019): 225.
  11. Charaf, S., Waedle, J.L., Sibbrit, D.W., et al. “Women's use of herbal and alternative medicines for preconception care.” N Z J Obstet Gynaecol 55.3 (2015): 222–6.
  12. Cerqueira, R.O., Frey, B.N., Leclerc, E., Brietzke, E. “Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review.” Arch Womens Ment Health 20.6 (2017): 713–9.
  13. Geum, J.Ch., Sung, W.H., Jung-Ho, Sh., Tak, K. “Effects of intensive training on menstrual function and certain serum hormones and peptides related to the female reproductive system.” Medicine (Baltimore) 96.21 (2017): e6876.
  14. Ghaima, K.K., Rasheed, S.F., Ahmed, E.F. “Antibiofilm, antibacterial and antioxidant activities of water extract of Calendula officinalis flowers.” International Journal of Biological & Pharmaceutical Research 4.7 (2013): 465–70.
  15. Iacovides, S., Avidon, I., Baker, F.C. “What we know about primary dysmenorrhea today: a critical review. Review article.” Hum Reprod Update 21.6 (2015): 762–8.
  16. Jacobson, M.H., Howards, P.P., Darrow, L.A., et al. “Thyroid hormones and menstrual cycle function in a longitudinal cohort of premenopausal women.” Paediatr Perinat Epidemiol 32.3 (2018): 225–34.
  17. Sessa, G., ed. Molecular Plant Immunity. Wiley-Blackwell, Tel-Aviv (2013).
  18. Pattanitum, P., Kunyanone, N., Brown, J., et al. “Dietary supplements for dysmenorrhea.” Cochraine Database Syst Rev 3 (2016): CD002124. DOI: 10.1002/14651858
  19. Samardzic, S., et al. “Antioxidant, anti-inflammatory and gastroprotective activity of Filipendula ulmaria (L.) Maxim. and Filipendula vulgaris.” Moench J Ethnopharmacology 213 (2018): 132–7.
  20. Sunni L. Mumford, Keewan Kim. “Subtle changes in menstrual cycle function – pieces of the puzzle.” Paediatr Perinat Epidemiol 32.3 (2018): 235–6.
  21. Schellenberg, R., Zimmermann, C., Drewe, J., et al. “Dose-dependent efficacy of the Vitex agnus castus extract Ze 440 in patients suffering from premenstrual syndrome.” Phytomedicine 19.14 (2012): 1325–31.
  22. Shynkovenko, I.L., Ilyina, Т.V., Kovalyova, А.М., et al. “Saponins of the extracts of Galium aparine and Galium verum.” Vìsnik farmacii 4.96 (2018): 16–22.
  23. Hassani, S., Namvar, M., Ghoreishvandi, M., et al. “Menstrual disturbances and hormonal changes in women workers exposed to a mixture of organic solvents in a pharmaceutical company.” Med J Islam Repub Iran 28 (2014): 156.
  24. van Die, D., Burger, H.G., Teede, H.J., Bone, K.M. “Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials.” Planta Med 79 (2013): 562–75.
  25. Vengerovskii, A.L, Suslov, N.I., Kaigorodtsev, A.V. “Correction of experimental anxiety behavior by meadowsweet (Filipendula vulgaris) extracts.” Exp Klin Farmacol 74.9 (2011): 3–6.



How to Cite

Грищенко, О. В., & Бобрицкая, В. В. (2019). Pathogenetic substantiation of advantages and duration of phytoselective therapy of the menstrual cycle disorders. REPRODUCTIVE ENDOCRINOLOGY, (48), 13–21.